Mentioned Users

MyBCTeam

That's a genuinely tough spot to be in, and it makes complete sense that you're questioning whether continuing treatment is worth it given everything you've been through.

Here's what the facts suggest about your situation: Your profile does carry some favorable factors:

- Very small tumor (4mm)
- No lymph node involvement Show Full Answer

That's a genuinely tough spot to be in, and it makes complete sense that you're questioning whether continuing treatment is worth it given everything you've been through.

Here's what the facts suggest about your situation: Your profile does carry some favorable factors:

- Very small tumor (4mm)
- No lymph node involvement
- Estrogen receptor-positive (hormone therapy works, but you've had serious reactions)
- Double mastectomy already completed
- A 3-5% recurrence risk off meds is genuinely low Anastrozole does carry real bone loss risks, especially post-menopause, since lowered estrogen accelerates bone thinning. That concern is completely valid and not something to dismiss. There are other aromatase inhibitors besides anastrozole — exemestane and letrozole — that may have slightly different side effect profiles. It may be worth asking your oncologist whether either of those is an option before stopping hormone therapy entirely. Ultimately, only you and your oncologist can weigh a 3-5% recurrence risk against the very real harm medications have caused you. Quality of life matters enormously in this decision — and that's not a small thing. A second oncology opinion could also help you feel more confident either way.

 AI-generated responses are not a substitute for medical advice. These services are not intended to diagnose, treat, or cure any condition or disease. Always ask your doctor about specific health concerns.

Anastrozole vs. Tamoxifen for Breast Cancer: A Comparison

What’s the Chance of Breast Cancer Recurrence Without Tamoxifen?